Natriuretic peptide pathways in heart failure: further therapeutic possibilities.

"Conflict of interests: S.J.S. is listed as an inventor on pending patents related to designer NP therapeutics, including CRRL408, filed by the Mayo Foundation for Medical Education and Research. H.H.C. is listed as an inventor on issued and/or patents related to designer NP therapeutics, including ANX042 (ASBNP.1), filed by the Mayo Foundation for Medical Education and Research. J.C.B. is listed as an inventor on issued and/or pending patents related to designer NP therapeutics, including cenderitide, ANX042 (ASBNP.1) and MANP, CRRL408, CRRL269 and NPA7, filed by the Mayo Foundation for Medical Education and Research. S.J.S. and J.C.B. are listed as inventors on pending patents related to small molecule GC-A enhancers, including MCUF-651, filed by the Mayo Foundation for Medical Education and Research and Sanford Burnham Prebys Medical Discovery Institute. S.J.S. and J.C.B. are listed as inventors on issued or pending patents, related to the use of CNP as a potential biomarker, filed by the Mayo Foundation for Medical Education and Research. S.J.S. and J.C.B. are listed as inventors on a pending patent, related the ex vivo human therapeutic potency assay, filed by the Mayo Foundation for Medical Education and Research. MANP and MCUF-651 has been licensed to E-Star Biotech and AlloRock, respectively. S.J.S., H.H.C., and J.C.B. serve on AlloRock’s scientific advisory board. All research is being conducted in compliance with Mayo Clinic conflict of interest policies. All other authors declared no conflict of interest."

"Funding This work was supported by the National Institutes of Health (R01HL158548, R01HL134688, R01HL136340, R01HL132854, R01HL084155, R01 HL136440, and R01DK103850 to S.J.S., H.H.C., and/or J.C.B.), the American Heart Association (16SDG29930003 to V.C.), and the Deutsche Forschungsgemeinschaft (DFG KU 1037/8-1, 12-1, 13-1, 14-1; SFB 1525 to M.K.)."